PATENT CLAIM ANALYSIS

Application Number: 16452984
Application Type: Utility
Filing Date: 2019-06
Publication Date: 2019-10
Patent Classification: ["424", "173100"]

Abstract:
The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-O and IFNγ production, induce CD4− T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Claim (Index 1):
A method of treatment of cancer in a patient in need thereof, the method comprising administering to the patient an antibody directed against human Inducible T-cell costimulator (ICOS), wherein said antibody reduces the number and/or activity of regulatory T cells (Treg cells) in a tumor microenvironment.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 100.0
- Lexical Diversity: 1.66667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15492520', '15165152', '14008423', '15387161', '16012867']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7778218409667672
- 35 USC 102 Novelty (BERT): 0.621168833480932
- Combined Prediction Score: 0.7621565402181837
- Mean Citation Score: 500.794714
- Max Citation Score: 600.4053299999998
- Similarity Product: 523.6876719990007

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test